NeOnc Technologies Announces Positive Phase 1 Results and Advances NEO212 into Phase 2 Trials
NeOnc Technologies Reports Promising Phase 1 Results and Sets Stage for Accelerated Phase 2 Development of NEO212
Key Highlights from the Report
- Phase 1 Dose-Escalation Achieves Maximum Tolerated Dose (MTD): NeOnc Technologies Holdings, Inc. (“NeOnc”, Nasdaq: NTHI) reached the MTD at 810 mg (Cohort 5) for its orally administered drug candidate NEO212. Dose escalation was halted after two Dose-Limiting Toxicities (DLTs), and the Recommended Phase 2 Dose (RP2D) is now set at 610 mg (Cohort 4).
- Early Signs of Clinical Efficacy: Despite Phase 1 being primarily a safety and tolerability study, NeOnc observed promising signs of anti-tumor activity, including indications of lasting disease control in heavily pretreated patients with recurrent glioblastoma (GBM) and brain metastases.
- Phase 2a Metastasis Cohort: The starting dose for this group will be 400 mg (Cohort 3), reflecting a cautious and data-driven approach to further dose exploration.
- First Oral Bioconjugated Temozolomide (TMZ) Platform Clinical Readout: This milestone validates NeOnc’s drug-engineering capabilities and supports the company’s expansion into oral as well as intranasal drug delivery for CNS cancers.
- Regulatory Progress: NeOnc has notified the FDA of the MTD and RP2D, and has submitted key regulatory documents (including MedWatch Form FDA 3500A and Form FDA 1571 via eCTD). The company plans to request a Type B (End-of-Phase 1) meeting with the FDA to discuss Phase 2 design and a potential Accelerated Approval pathway.
- Patent Protection: The NEO212 and NEO100 programs are protected by approximately ten issued patents and pending applications, providing robust intellectual property coverage through at least 2038.
Implications for Shareholders and Investors
- Clear Clinical Momentum: The identification of a safe and tolerable RP2D, combined with early efficacy signals, positions NeOnc for a pivotal, potentially registration-enabling Phase 2 study. This is a major de-risking milestone for the NEO212 program and could have significant positive implications for the company’s valuation.
- Potential to Redefine Brain Cancer Treatment: If future trials confirm its benefits, NEO212 could challenge or replace the current standard of care (TMZ, marketed as Temodar® by Merck) for glioblastoma, astrocytoma, and other aggressive CNS malignancies. NEO212 is specifically engineered to overcome TMZ’s main weakness—MGMT-mediated resistance—by inactivating and degrading the MGMT repair enzyme, a mechanism not achieved by standard TMZ therapy.
- First-in-Class Oral Chemotherapy: NEO212 is the first oral, chemically conjugated chemotherapy combining TMZ with NEO100 (a proprietary form of perillyl alcohol). This proprietary technology enhances blood-brain barrier penetration and antitumor activity, which could open new opportunities in CNS oncology where treatment options are limited.
- Regulatory Acceleration: The company is advancing under FDA Fast-Track and IND status, and is actively pursuing discussion for an Accelerated Approval pathway. Regulatory alignment and early engagement with the FDA are positive signals for investors regarding the pace of development and potential market entry.
- Strong Intellectual Property Position: With an extensive patent portfolio, NeOnc is well-positioned to protect its innovations and maintain long-term strategic value.
- Upcoming Catalysts: A pivotal conference call featuring NeOnc management and key opinion leaders (KOLs) was held on March 4, 2026, underscoring the significance of this clinical milestone and offering additional insights to investors.
Additional Details for Investors
- Clinical Trial Design and Next Steps: The transition into Phase 2 will focus on efficacy at the established RP2D within specific patient cohorts, aiming to generate robust clinical data to support potential accelerated regulatory pathways. NeOnc is preparing for further regulatory submissions and alignment as it moves toward a pivotal trial.
- Scientific Validation: The company has demonstrated its ability to engineer and clinically validate both oral and intranasal delivery of CNS-penetrant drugs, a feat not widely achieved in the field. The NEO212 program’s progress is viewed by both internal scientific leadership and external experts (such as Dr. Henry Friedman of Duke University) as a foundational step for future success in CNS cancer therapeutics.
- Market Opportunity: With a focus on recurrent CNS cancers, including glioblastoma, the addressable market is significant, and there remains a high unmet need for new, effective oral therapies.
About NeOnc Technologies Holdings, Inc.
NeOnc Technologies is a clinical-stage biopharmaceutical company developing innovative therapies for central nervous system disorders, with a strong focus on overcoming the blood-brain barrier. The company’s lead candidates, NEO100 and NEO212, are both in Phase II clinical trials and benefit from FDA Fast-Track and IND status. NeOnc exclusively licenses a robust global patent portfolio from the University of Southern California.
For further information, visit https://neonc.com
Conference Call Replay
Investors can access the webcast replay at: Webcast Replay or by visiting the investor relations section at NeOnc Investor Relations.
Contact Information
Disclaimer
This article contains forward-looking statements, including but not limited to the future development and potential regulatory approval of NEO212, anticipated benefits over current standards of care, and expectations for future clinical outcomes. Actual results may differ materially due to a variety of risks and uncertainties, including those detailed in NeOnc Technologies’ filings with the Securities and Exchange Commission. Investors should not rely solely on these statements and are encouraged to review all company filings and consult with their financial advisors. This article is for informational purposes only and does not constitute investment advice.
View NEONC TECHNOLOGIES HOLDINGS, INC. Historical chart here
